Cargando…

Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation

Red blood cells (RBCs) are an excellent choice for cell preparation research because of their biocompatibility, high drug loading, and long half-life. In this study, doxorubicin (DOX) was encapsulated with RBCs as the carrier. The biotin-avidin system binding principle was used to modify biotinylate...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chen, Wang, Min, Zhang, Yan, Jia, Hongxin, Chen, Binbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091773/
https://www.ncbi.nlm.nih.gov/pubmed/35582403
http://dx.doi.org/10.1016/j.jpha.2021.06.003
_version_ 1784705002421354496
author Wang, Chen
Wang, Min
Zhang, Yan
Jia, Hongxin
Chen, Binbin
author_facet Wang, Chen
Wang, Min
Zhang, Yan
Jia, Hongxin
Chen, Binbin
author_sort Wang, Chen
collection PubMed
description Red blood cells (RBCs) are an excellent choice for cell preparation research because of their biocompatibility, high drug loading, and long half-life. In this study, doxorubicin (DOX) was encapsulated with RBCs as the carrier. The biotin-avidin system binding principle was used to modify biotinylated cyclic arginine-glycine-aspartic acid (cRGD) onto RBC surfaces for accurate targeting, high drug loading, and sustained drug release. The RBC drug delivery system (DDS) was characterized, and the concentration of surface sulfur in the energy spectrum was 6.330%. The physical and chemical properties of RBC DDS were as follows: drug content, 0.857 mg/mL; particle size, 3339 nm; potential value, −12.5 mV; and cumulative release rate, 81.35%. There was no significant change in RBC morphology for up to seven days. The results of the targeting and cytotoxicity studies of RBC DDS showed that many RBCs covered the surfaces of U251 cells, and the fluorescence intensity was higher than that of MCF-7 cells. The IC(50) value of unmodified drug-loaded RBCs was 2.5 times higher than that of targeted modified drug-loaded RBCs, indicating that the targeting of cancer cells produced satisfactory inhibition. This study confirms that the RBC DDS has the characteristics of accurate targeting, high drug loading, and slow drug release, which increases its likelihood of becoming a clinical cancer treatment in the future.
format Online
Article
Text
id pubmed-9091773
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Xi'an Jiaotong University
record_format MEDLINE/PubMed
spelling pubmed-90917732022-05-16 Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation Wang, Chen Wang, Min Zhang, Yan Jia, Hongxin Chen, Binbin J Pharm Anal Original Article Red blood cells (RBCs) are an excellent choice for cell preparation research because of their biocompatibility, high drug loading, and long half-life. In this study, doxorubicin (DOX) was encapsulated with RBCs as the carrier. The biotin-avidin system binding principle was used to modify biotinylated cyclic arginine-glycine-aspartic acid (cRGD) onto RBC surfaces for accurate targeting, high drug loading, and sustained drug release. The RBC drug delivery system (DDS) was characterized, and the concentration of surface sulfur in the energy spectrum was 6.330%. The physical and chemical properties of RBC DDS were as follows: drug content, 0.857 mg/mL; particle size, 3339 nm; potential value, −12.5 mV; and cumulative release rate, 81.35%. There was no significant change in RBC morphology for up to seven days. The results of the targeting and cytotoxicity studies of RBC DDS showed that many RBCs covered the surfaces of U251 cells, and the fluorescence intensity was higher than that of MCF-7 cells. The IC(50) value of unmodified drug-loaded RBCs was 2.5 times higher than that of targeted modified drug-loaded RBCs, indicating that the targeting of cancer cells produced satisfactory inhibition. This study confirms that the RBC DDS has the characteristics of accurate targeting, high drug loading, and slow drug release, which increases its likelihood of becoming a clinical cancer treatment in the future. Xi'an Jiaotong University 2022-04 2021-06-12 /pmc/articles/PMC9091773/ /pubmed/35582403 http://dx.doi.org/10.1016/j.jpha.2021.06.003 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Wang, Chen
Wang, Min
Zhang, Yan
Jia, Hongxin
Chen, Binbin
Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation
title Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation
title_full Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation
title_fullStr Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation
title_full_unstemmed Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation
title_short Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation
title_sort cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: synthesis and in vitro evaluation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091773/
https://www.ncbi.nlm.nih.gov/pubmed/35582403
http://dx.doi.org/10.1016/j.jpha.2021.06.003
work_keys_str_mv AT wangchen cyclicarginineglycineasparticacidmodifiedredbloodcellsfordrugdeliverysynthesisandinvitroevaluation
AT wangmin cyclicarginineglycineasparticacidmodifiedredbloodcellsfordrugdeliverysynthesisandinvitroevaluation
AT zhangyan cyclicarginineglycineasparticacidmodifiedredbloodcellsfordrugdeliverysynthesisandinvitroevaluation
AT jiahongxin cyclicarginineglycineasparticacidmodifiedredbloodcellsfordrugdeliverysynthesisandinvitroevaluation
AT chenbinbin cyclicarginineglycineasparticacidmodifiedredbloodcellsfordrugdeliverysynthesisandinvitroevaluation